Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients

BACKGROUND: The role of piperacillin/tazobactam for treatment of serious infections due to AmpC-producing organisms remains debatable, particularly in immunocompromised patients. METHODS: This was a retrospective cohort study in immunocompromised patients that investigated the effect of definitive t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Brian, Wong, Miranda, Ha, David, Bounthavong, Mark, Banaei, Niaz, Deresinski, Stanley, Diep, Calvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068414/
https://www.ncbi.nlm.nih.gov/pubmed/36879495
http://dx.doi.org/10.1093/jac/dkad037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068414/
https://www.ncbi.nlm.nih.gov/pubmed/36879495
http://dx.doi.org/10.1093/jac/dkad037

Ejemplares similares